Oncologia.mx - Best of American Society of Clinical Oncology (ASCO) Cd. de México 2013
Inicio | Noticias | Nacional | Best of American Society of Clinical Oncology (ASCO) Cd. de México 2013

Best of American Society of Clinical Oncology (ASCO) Cd. de México 2013

Por
Best of American Society of Clinical Oncology (ASCO) Cd. de México 2013

Programa de Actividades 18 - 21 Septiembre

A continuación nos permitimos reproducir el programa de actividades del Congreso "Best of ASCO 2013 Cd. de México", que se lleva a cabo del 18 al 21 de Septiembre, en el Centro de Convenciones "Cinia González Diez" en el Hospital de la Beneficiencia Española, en Polanco.

 

ENFERMERIA ONCOLOGICA

Septiembre 18, 2013 (Miércoles)

 

8:00  - Desayuno con el Experto: Salón Victoria - Manejo de nuevas drogas en cáncer de mama, del consultorio al cuarto de infusión - Dr. N. Flores, HRZ 1ro. Octubre

9:00 - Inauguración

9:30 - Calidad Eficacia y Seguridad de los medicamentos oncológicos - Dr. Abdiel Esquivel

10:00 - Minimización de las Reacciones adversas en Oncología - Dra. Ilian Arsof Saab

10:30 - Prevención y Tratamiento de Linfedema - Dra. Isabelle Aloi-Timeus S

11:30 - Café

12:00 - Estándares de Atención - Dr. Ramiro Jesús, UNAM

12:30 - Situación Farmacológica del Paciente con Quimioterapia - Dra Patricia Cortes, CMN 20 de Nov

13:00 - Reducción De Riesgos en la preparación de QT - Lic. Enf. Janet Román Téllez, CMN 20 de Noviembre

13:30 - Nutrición y Quimioterapia - Dra Julene Bosch, CMN 20 de Noviembre

14:00 - Comida

15:30 - Seguridad en la Terapia de Infusión Oncológica - Dra Aida Castillo Ferrari, Bbraun

16:30 - Cuidados Paliativos - Dr. Pierre Clemenceau, INCan

17:00 - Estándares de Certificación Hospitalaria - Lic. Enf Maciel Rodríguez, CMN Siglo XXI

17:30 - Desarrollo y futuro de la Enfermería Oncológica - Lic. Enf Rogelio Rodríguez, INCan

 

PROGRAMA ACADEMICO MÉDICO

Septiembre 19, 2013 (jueves)

 

Desayunos con el Experto

8:00 - Salón Montejo - Panorama en el Tratamiento del cáncer de mama Triple negativo - Ponente Dra. L Torrecillas, CMN 20 de Noviembre

8:00 - Salón Victoria - Osteosarcoma - Ponente Dr. MA Palomo Colli

 

--------------------

Breast

Coordinador - Dr. M. Lázaro, Jefe de Servicio de Quimioterapia, Hospital General de México

Ponentes - Carlos Robles Vidal, Instituto Nacional de Cancerología INCan - Mario Escobar Gómez, Hospital General de México

9:00 - A randomized phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast ca patients 10 Yr follow up results of

NSABP B 32

9:15 - Radiotherapy or surgery of the axilla after positive sentinel node in Breast ca patients

9:30 - A randomized phase II trial investigating the addition of Carboplatin to neoadjuvant therapy for triple negative and HER2 positive early breast ca.

9:45 - Comparison of Doxorubicin and cyclophosphamide vs single-agent paclitaxel as adjuvant therapy for breast ca in women with 0-3 positive axillary nodes

 

--------------------

Breast Her 2

Coordinador - Dra. Laura Torrecillas, Vice Presidente SMeO

Ponentes - Dr. A. Juárez, CMN 20 de Noviembre - Dr. F. Aldaco, CMN 20 de Noviembre

10:00 - aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years vs. Stopping at 5 years. In 6953 women with early breast ca.

10:15 - Clinical and translational results of CALGB 40601: A Neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2 /ER - HER2 +

10:30 - ACOSOG Z1041 (Alliance) : Definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus Trastuzumab (FEC P+T) with paclitaxel plus Trastuzumab followed by FEC plus Trastuzumab in HER2 + operable breast ca.

10:45 - Array and DNA sequencing to personalize targeted treatment of metastatic breast ca. Patients (SAFIR01)

11:00 - Genetic Alterations and Everolimus Efficacy in Hormone Receptor-positive, HER2-negative Advanced Breast Cancer: results from BOLERO 2

11:15 - Mesa Redonda Ponentes y Coordinador

--------------------

11:30 - Coffee Break


--------------------

GYN

Coordinador - Dra. Dolores Gallardo, INCan / Presidente GICOM

Ponente - Dr. Bradley J. Monk, Phoenix, Arizona US

12:00 - Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a Phase III randomized trial of the Gynecologic Oncology Group

12:15 - Chemotherapy or upfront surgery for newly diagnosed advance ovarian cancer: Results from the MRC CHORUS trial

12:30 - Olaparib maintenance tharpy in pts with platinun-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm)

12:45 - A randomized multicenter Phase III study comparing weekly versus every 3 weeks carboplatin plus paclitaxel in pts with advacned ovarian ca.: Multicentic Italian Trials in Ovarian Cancer

13:00 - Randomized, double-blind, phase III trial of pazopanib vs placebo in women who have not progresses after 1s-line chomotherapy advanced epithelial ovarian, fallopian tube , or primary peritoneal ca.: results of an international Intergroup trial

13:15 - Effect of visual inspection with acetic acid(VIA) screenig by primary health workers on cervical cancer mortality: a cluster randomized controlled trial in Mumbai India


--------------------

H&N

Coordinador - Dr. Roman Basaure, Jefe de Oncología, Hospital General

Ponente - Dr. Ricard Mesia N., Institut Catalá d'Oncología, Barcelona España

13:30 - Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated Thyroid Ca

13:45 - Novedades de ASCO 2013 en Cabeza y Cuello   

--------------------

Preferable on Workup of the abnormal CBC - Dr. D Jones Quest Diagnostics

14:00 - Working Lunch - Salón Victoria

--------------------


Lung

Coordinador - Dr. Jaime De la Garza, Instituto Nacional de Cancerología INCan

Ponente - Dr. J Alatorre, Instituto Nacional de Enfermedades Respiratorias INER 

15:30 - A randomized phase III comparison of standard-dose vr high dose conformal chemoradiotherapy with or without cetuximab for stage III non -small cell lung ca. : results on radiation dose in RTOG 0617

15:45 - Neoadjuvant chemotherapy with or without preoperative irradiation in stage IIIa/N2 NSCLC: a randomized phase III trial by the Swiss Group for Clinical Cancer Research

16:00 - Chemotherapy with or without maintenance sunitinib for untreated extensive.stage Small cell lung ca.

 

--------------------

Lung mets

Coordinador - Dr. Pedro Escudero, Dir. Hospital Oncología CMN Siglo XXI

Ponente - Dra. Y. Bautista, CMN Siglo XXI

16:15 - Clinical activity, safety and biomarkers of MPDL3280A, an engineered PD-L1 antibody in pts with locally advanced or metastatic NSCLC

16:30 - Clinical activity of the ALK inhibitor LDK378 in advanced ALK-positive NSCLC

16:45 - Randomized, open-label, phase III study of pemetrexed+ carboplatin followed by maintenance pemetrexed vs paclitaxel+carboplatin+bevacizumab folloed by maintenanace bevacizumab in pts with advanced nonsquamous NSCLC

17:00 - Randomized proteomic stratified phse III study of the second line erlotinib vs. Chemotherapy in pts with inoperable NSCLC

17:15 - Nintedanib (BIBF 1120)+ docetaxel in NSCLC pts progressing after first line chemotherapy LUME lung 1, a randomized, double-bliend phase 3 trial


--------------------

Oncología Pediátrica

17:30

Coordinador - Dra. R. Cárdenas, Jefe de Oncología INP

Ponente - Dr. R. Rivera Luna, Onco Hemato INP


--------------------

18:00 - Simposium Satelite : Erivedge Eficacia y Seguridad de largo plazo de Vismodegib en pacientes con Carcinoma de Células Basales avanzado (aBBC)

Ponente: Dra Rosa Ma. Ponce, Hosp General de México SS

--------------------

20:00 - PRELIMINAR

--------------------

22:00 - Cena Simposio Satelite - Dr. Ricardo Álvarez, MD Anderson Cáncer Center (Salón Victoria)

 

PROGRAMA ACADEMICO MÉDICO

Septiembre 20, 2013 (Viernes)

 

Desayunos con el Experto

8:00 – Salón Montejo - Revisión de la Controversia en el tratamiento de NSCLC en 1a y 2a línea, Dr J Alatorre INER

8:00 – Salón Victoria - "Nuevo algoritmo de manejo en el paciente con CCRm" - Dra. L Torrecillas CMN 20 de Nov.


--------------------

CRC

Coordinador - Dr. G Calderillo, Jefe de Servicio Oncología INCan

Ponentes - Dr G. Méndez, Fund Favaloro Bs. As. Arg. - Dra Consuelo Diaz Romero, INCan

9:00 - randomized clinical trial of Chemotherapy compared to Chemotherapy in combination with Cetuximab in Kras wildtype pts with operable mets from Colorectal ca.

9:15 - Analysis of overall survival and safety during the course of the phase III VELOUR trial comparing FOLFIRI and ziv-aflibercept or placebo in mCRC patients who progressed on prior oxaliplatin treatment.

9:30 - Analysis of KRAS/NRAS Mutations in PEAK: a Randomized Phase 2 Study of FOLFOX6+ Panitumumab or Bevacizumab as 1st line treatment for Wild Type KRAS (exon 2) Metastatic Colorectal Ca.

9:45 - Randomized comparison of FOLFIRI plus cetuximab vs FOLFIRI plus Bevacizumab as 1s line treatment of KRAS wildtype mCRC

10:00 - Maintenance Treatment with Capecitabine and Bevacizumab vs observation after induction treatment with Qt and Bevacizumab in metastatic Colorectal C.

10:15 - FOLFOXIRI/bevacizumab vs FOLFIRI/bev as first line treatment in uresecable metastatic colorectal ca.

10:30 - Maintenance therapy with Bevacizumab with or without erlotinib in mCRC according to KRAS


--------------------

GI NON CRC

Coordinadores - Dra. G Cervantes, Jefe de Oncología, CMN20 de Nov - Dr. R Medrano, Jefe de Serv. Sarcomas CMN Siglo XXI

Ponentes - Dr G Calderillo, INCan - Dr A. Juarez, CMN 20 de Nov

10:45 - Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine vs. Gemcitabine alone for patients with metastatic adenocarcinamoa of the pancreas with PET and CA19-9

11:00 - Lapatinib in combination with capecitabine plus oxiliplatin (CapeOX) in HER2 positive advanced or metastatic gastric esophageal, or gastro-esophageal adenocarcinoma

11:15 - SAMIT: a phase III randomized clinical trial of adjuvant paclitaxel followed by oral flourinated pyrimidines for locally advanced gastric ca.

11:30 - Comparison of Chemoradiotherapy and Chemotherapy in patients with locally advanced pancreatic ca. Controlled after 4 months of gemcitabine with or without erlotinib

--------------------

11:45 - Coffe Break


--------------------

CNS

Coordinador - Dr Alejandro Silva, Jefe de Oncología del CMN Siglo XXI

Ponentes - Dra Y. Bautista - M. Pérez, CMN Siglo XXI

12:15 - RTOG 0825: Phase III double blind placebo controlled trial evaluating Bevacizumab in pts with newly diagnosed Glioblastoma

12:30 - A randomized phase II study of Bevacizumab vs. Bevacizumab plus lomustine single agent in recurrent Glioblastoma

12:45 - A randomized phase II study of Bevacizumab vs. Bevacizumab plus lomustine single agent in recurrent Glioblastoma

13:00 - Bevacizumab, irinotecan, and radiotherapy vs standard Temozolomide and Radiotherapy in newly diagnosed MGMT


--------------------

Melanoma

Coordinador - Dr Jorge Robles, Jefe de Oncología del Hospital PEMEX Sur

Ponente - Dr Mario Pérez, PEMEX Sur

 

13:15 - Multicenter, ramdomized phase II trial of GM-CSF plus ipilimumab vs ipi alone in metastatic melanoma

13:30 - Clinical efficacy and safety of lambrolizumab (MK-3475, antiPD-1 monoclonal antibody) in pts with advanced melanoma

13:45 - Safety and clinical activity of nivolumab in combination with ipilimumab in pts with advanced melanoma

14:00 - OPTiM: a randomized phase 3 trial of talimogene laherparepvec (T-VEC) vs subcutaneous GM-CSF for the treatment of unresected stage IIIB/C and IV melanoma

--------------------

“Biocomparables en la Medicina: ¿Por qué son una opción válida?” - Dr. A Figueroa, CINVESTAV - Dr. E Medina, IPICYT - Mtro M Elizondo, Instituto Nacional de Salud Pública

14:15 - Working Lunch - Salón Victoria


--------------------

GU

Coordinador - Dra P Cabrera, Jefa de Serv. Oncología ISSEMYM

Ponente - Dr Francisco Javier Orlandi, Chile

15:45 - Interim analysis of a compassionate-use program (CUP) and early access program (EAP) providing cabazitaxel (Cbz) plus prednisone (P) to patients (pts) with metastasic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel.

16:00 - A phase III trial of personalized chemotherapy based on serum tumor marker decline in poor prognosis germ cell tumors

16:15 - Duration of Androgen deprivation therapy in high risk prostate cancer

16:30 - Long term safety and efficacy analysis of abiraterone acetate plus prednisone inmetastatic castration resistant prostate cancer without prior chemo

--------------------

16:45

Supportive Care in Cancer GU

Coordinador - Dr. R Villalobos, Jefe de Serv. Oncología CMN La Raza

Ponente - Dr. R Clemenceau, Representante de MASCC Mexico

--------------------

17:15 - Reconocimiento a Residentes de Oncología

--------------------

18:00 - Ceremonia Protocolaria  de Clausura de Actividades - Vino de Honor


 

PROGRAMA PARA ONG's, FAMILIARES Y PACIENTES CON CÁNCER

Septiembre 21, 2013 (Sábado)

 

9:00 - Inauguración

9:30 - Vivir con Ca. De Próstata - Pregúntale al experto - Video + ponencia

10:00 - Efectos secundarios de los medicamentos oncológicos ¿cómo prevenirlos o minimizarlos? - Dra Ilian Arsof Saab

10:30 - Centro de Apoyo para la Atención Integral CAAI - PS Raquel Menéndez Aponte

11:30 - Coffee Break

12:00 - Módulo de Navegación INCan - Dra Laura Suchil, INCan

12:30 - Asoc. Mex de Lucha vs Cáncer - Dra Ma. Teresa Cisneros

13:00 - Apoyo Emocional durante la Enfermedad - Mtra Gina Tarditi

13:30 - Bases Nutricionales para el Paciente Oncológico - Dra Julene Bosch, CMN 20 de Nov

14:00 - Comida

15:30 - Prevención y Tratamiento de Linfedema - Isabelle Aloi-TimeusS

16:00 - Calidad de Vida - Isabelle Aloi-Timeus S

16:30 - ONG Rebecca de Alba - Lic Miryana Pérez

17:00 - ONG Ave Fenix - Dra Patricia Cortés

17:30 - Voz del Cáncer - ONG Rebecca de Alba

  • Enviar a amistad Enviar a amistad
  • Imprimir Imprimir
  • Texto sin formato Texto sin formato

Etiquetado como:

Calendario

Califica este artículo

0